Fritz Janicke
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Journal: Cancers
Published: February 01, 2023
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 17, 2016
Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer.
Journal: Molecular medicine reports
Published: November 10, 2015
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 12, 2015
Systemic treatment of vulvar cancer.
Journal: Expert review of anticancer therapy
Published: May 22, 2015
8p deletion is strongly linked to poor prognosis in breast cancer.
Journal: Cancer biology & therapy
Published: May 12, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancer.
Journal: BMC cancer
Published: February 09, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Journal: Breast cancer research and treatment
Published: February 05, 2015
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
Journal: OncoTargets and therapy
Published: December 16, 2014
Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
Journal: Oncology reports
Published: July 30, 2014
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 16, 2014
Last Updated: 09/26/2026